Netherlands' IMCD H1 revenue rises 11%
Netherlands' IMCD H1 revenue rises 11%
Overview
Netherlands specialty chemicals distributor's H1 revenue rose 11% on constant currency basis
Gross profit and EBITA for H1 increased 7% and 8% respectively on constant currency basis
Company completed acquisitions in South Korea and Ireland/UK, signed agreement in Thailand
Result Drivers
ORGANIC GROWTH - Co said gross profit and EBITA growth in H1 was achieved organically
ACQUISITIONS - Co completed acquisitions in South Korea and Ireland/UK and signed an agreement in Thailand
Company press release: ID:nGNE4FrMQ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 EBITA |
| EUR 285 mln |
|
H1 Free Cash Flow |
| EUR 222 mln |
|
H1 Gross Profit |
| EUR 658 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy"
Wall Street's median 12-month price target for IMCD NV is €115.00, about 29.9% above its July 28 closing price of €88.52
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago
Reuters Recommended Reads
July 28 - UK chemicals maker Croda beats interim profit market view on solid demand, price hikes
July 28 - Ashland Q3 profit beats on higher volume, pricing; cuts FY EPS forecast
July 28 - EU to impose provisional duties on Chinese sodium benzoate
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)